Anonymous
Not logged in
Talk
Contributions
Create account
Log in
Search
Editing
Calcitonin gene-related peptide monoclonal antibody
From MEpedia, a crowd-sourced encyclopedia of ME and CFS science and history
Namespaces
Page
Discussion
More
More
Page actions
Read
Edit
Edit source
History
Warning:
You are not logged in. Your IP address will be publicly visible if you make any edits. If you
log in
or
create an account
, your edits will be attributed to your username, along with other benefits.
Anti-spam check. Do
not
fill this in!
{{stub}} '''Calcitonin gene-related peptide monoclonal antibodies''' (mAbs) or '''CGRP mAbs''' are a new type of preventative [[migraine]] treatment.<ref name="migrainetrust">{{Cite web | url = https://migrainetrust.org/live-with-migraine/healthcare/treatments/calcitonin-gene-related-peptide-monoclonal-antibodies/ | title = Calcitonin Gene-Related Peptide (CGRP) monoclonal antibodies | website = The Migraine Trust|language=en-US | access-date = 2021-10-12}}</ref><ref name="drugscom" /> CGRP mAbs block the release of calcitonin gene-related peptide, a neurotransmitter known to cause migraines. Unlike known the small molecule CGRP antagonists known as [[:Category:Gepants|gepants]], CGRP mAbs are used for preventation rather than treatment of an existing migraine.<ref name="drugscom">{{Cite web | url = https://www.drugs.com/medical-answers/new-drugs-treatment-prevention-migraine-3515053/ | title = What are the new drugs for the treatment of migraines? | website = Drugs.com|language=en | access-date = 2021-10-12}}</ref><ref name="gepants">{{Cite journal | last = Negro | first = Andrea | author-link = | last2 = Martelletti | first2 = Paolo | author-link2 = | date = Jun 2019 | title = Gepants for the treatment of migraine | url =https://pubmed.ncbi.nlm.nih.gov/31081399/ | journal = Expert Opinion on Investigational Drugs | volume = 28 | issue = 6 | pages = 555–567|doi=10.1080/13543784.2019.1618830|issn=1744-7658|pmc=|pmid=31081399|access-date=|quote=|via=}}</ref> ==Drugs== Currently FDA-licensed CGRP mAbs are: *[[Eptinezumab]] (Vyepti), approved in 2020 *[[Erenumab]] (Aimovig), approved in 2018 *[[Fremanezumab]] (Ajovy), approved in 2018 *[[Galcanezumab]] (Emgality), approved in 2018<ref name="drugscom" /> == Uses == A small retrospective chart review by Kang and Govindarajan (2020) found that CGRP mAbs also significantly decreased peripheral nerve [[pain]] in patients who also had migraines.<ref>{{Cite journal | last = Kang | first = Seung Ah | last2 = Govindarajan | first2 = Raghav | date = 2021 | title=Anti-calcitonin gene–related peptide monoclonal antibodies for neuropathic pain in patients with migraine headache | url =https://onlinelibrary.wiley.com/doi/abs/10.1002/mus.27153 | journal = Muscle & Nerve|language=en | volume = 63 | issue = 4 | pages = 563–567|doi=10.1002/mus.27153|issn=1097-4598}}</ref> ==News and articles == *2020, [https://www.theguardian.com/society/2021/oct/09/can-migraines-be-untangled-by-new-medical-thinking Can migraines be untangled by new medical thinking?] - The Observer ==Learn more == *[https://migrainetrust.org/live-with-migraine/healthcare/treatments/calcitonin-gene-related-peptide-monoclonal-antibodies/ Calcitonin gene-related peptide monoclonal antibodies] - The Migraine Trust *[https://www.migraine.org.au/cgrp CGRP Medications] - Migraine Australia ==See also == *[[Migraine]] *[[Calcitonin gene-related peptide]] (CGRP) ==References == {{Reflist}} [[Category:CGRP antagonists]] [[Category:Analgesics]] [[Category:Antibodies]] [[Category:Potential treatments]] [[Category:Antimigraine agents]]
Summary:
Please make sure your edits are consistent with
MEpedia's guidelines
.
By saving changes, you agree to the
Terms of use
, and you irrevocably agree to release your contribution under the
CC BY-SA 3.0 License
and the
GFDL
. You agree that a hyperlink or URL is sufficient attribution under the Creative Commons license.
Cancel
Editing help
(opens in new window)
Templates used on this page:
Template:Asbox
(
edit
)
Template:Cite journal
(
edit
)
Template:Cite web
(
edit
)
Template:Full stop
(
edit
)
Template:Full stop character
(
edit
)
Template:GetFallback
(
edit
)
Template:Help improve text
(
edit
)
Template:LangSwitch
(
edit
)
Template:Main other
(
edit
)
Template:No fullstop
(
edit
)
Template:No fullstop/first
(
edit
)
Template:Reflist
(
edit
)
Template:Str endswith
(
edit
)
Template:Stub
(
view source
) (semi-protected)
Template:Stub text
(
edit
)
Template:Uselang
(
edit
)
Module:Arguments
(
edit
)
Module:Asbox
(
edit
)
Module:Buffer
(
edit
)
Module:Check for unknown parameters
(
edit
)
Module:Citation/CS1
(
edit
)
Module:Citation/CS1/COinS
(
edit
)
Module:Citation/CS1/Configuration
(
edit
)
Module:Citation/CS1/Date validation
(
edit
)
Module:Citation/CS1/Identifiers
(
edit
)
Module:Citation/CS1/Utilities
(
edit
)
Module:Citation/CS1/Whitelist
(
edit
)
Module:Navbar
(
edit
)
Module:No globals
(
edit
)
Module:String
(
edit
)
This page is a member of 2 hidden categories:
Category:All stub articles
Category:Stub pages last edited in 2023
Navigation
Navigation
Skip to content
Main page
Browse
Become an editor
Random page
Popular pages
Abbreviations
Glossary
About MEpedia
Links for editors
Contents
Guidelines
Recent changes
Pages in need
Search
Help
Wiki tools
Wiki tools
Special pages
Page tools
Page tools
User page tools
More
What links here
Related changes
Page information
Page logs